SAN DIEGO--(BUSINESS WIRE)--Aug. 23, 2016--
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company
focused on the development and commercialization of innovative medicines
to address unmet medical needs in central nervous system disorders,
today announced that the underwriters for the Company’s previously
announced public offering have fully exercised their option to purchase
an additional 909,090 shares. All 6,969,696 shares sold in the offering
were offered by ACADIA at a price to the public of $33.00 per share, for
total gross proceeds to ACADIA of approximately $230.0 million before
deducting underwriting discounts and commissions and other offering
expenses payable by ACADIA. The closing of the sale of 6,060,606 shares
was completed on August 15, 2016, and the closing of the sale of 909,090
shares pursuant to the full exercise by the underwriters of their option
to purchase additional shares was completed earlier today.
J.P. Morgan Securities LLC, Goldman, Sachs & Co. and BofA Merrill Lynch
acted as the joint book-running managers for the offering. Cowen and
Company, LLC, Piper Jaffray & Co. and Needham & Company, LLC acted as
co-managers for the offering.
The shares of common stock described above were offered by ACADIA
pursuant to a shelf registration statement filed by ACADIA with the
Securities and Exchange Commission (SEC) that became automatically
effective on March 3, 2014. A final prospectus supplement and
accompanying prospectus relating to the offering have been filed with
the SEC and are available on the SEC’s website located at http://www.sec.gov.
Copies of the final prospectus supplement and the accompanying
prospectus related to this offering may be obtained from J.P. Morgan
Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island
Avenue, Edgewood, NY 11717, or by telephone at (866) 803-9204, or by
email to: firstname.lastname@example.org,
or from Goldman, Sachs & Co., Attention: Prospectus Department, 200 West
Street, New York, NY 10282, or by telephone at (866) 471-2526, or by
email to: email@example.com,
or from BofA Merrill Lynch, NC1-004-03-43, 200 North College Street, 3rd
floor, Charlotte, NC 28255-0001, Attention: Prospectus Department, or by
email to: firstname.lastname@example.org.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy these securities, nor shall there be any
sale of these securities in any state or other jurisdiction in which
such offer, solicitation or sale would be unlawful prior to the
registration or qualification under the securities laws of any such
state or other jurisdiction.
About ACADIA Pharmaceuticals
ACADIA is a biopharmaceutical company focused on the development and
commercialization of innovative medicines to address unmet medical needs
in central nervous system disorders.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160823006265/en/
Source: ACADIA Pharmaceuticals Inc.
ACADIA Pharmaceuticals Inc.
Lisa Barthelemy, Senior
Director, Investor Relations